Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLRB Stock Forecast 2026-2027
$2.51
Current Price
$20.86M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CLRB Price Targets
+497.6%
To High Target of $15.00
+318.3%
To Median Target of $10.50
+298.4%
To Low Target of $10.00
CLRB Price Momentum
-11.0%
1 Week Change
-10.0%
1 Month Change
-49.7%
1 Year Change
-14.9%
Year-to-Date Change
-61.5%
From 52W High of $6.52
+14.1%
From 52W Low of $2.20
📊 TOP ANALYST CALLS
Did CLRB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cellectar is one of their latest high-conviction picks.
Latest CLRB Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CLRB has a bullish consensus with a median price target of $10.50 (ranging from $10.00 to $15.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $2.51, the median forecast implies a 318.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Kevin DeGeeter at Ladenburg Thalmann, suggesting a 298.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLRB Analyst Ratings
4
Buy
0
Hold
0
Sell
CLRB Price Target Range
Low
$10.00
Average
$10.50
High
$15.00
Current: $2.51
Latest CLRB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLRB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | Ladenburg Thalmann | Kevin DeGeeter | Buy | Assumes | $10.00 |
| Mar 10, 2026 | Maxim Group | Buy | Upgrade | $N/A | |
| May 14, 2025 | Maxim Group | Hold | Downgrade | $N/A | |
| Dec 11, 2024 | Oppenheimer | Perform | Downgrade | $N/A | |
| Nov 19, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Oct 11, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $14.00 |
| Mar 28, 2024 | Roth MKM | Buy | Maintains | $N/A | |
| Mar 28, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Mar 4, 2024 | Roth MKM | Buy | Reiterates | $N/A | |
| Nov 4, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 18, 2022 | Oppenheimer | Jeff Jones | Outperform | Assumes | $5.50 |
| Nov 25, 2020 | Maxim Group | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Oppenheimer | Outperform | Initiates | $N/A | |
| Nov 25, 2020 | Roth Capital | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Brookline Capital | Buy | Initiates | $N/A | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Jul 1, 2020 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jun 23, 2020 | Maxim Group | Buy | Initiates | $N/A | |
| Sep 13, 2019 | Roth Capital | Buy | Initiates | $N/A |
Cellectar Biosciences, Inc. (CLRB) Competitors
The following stocks are similar to Cellectar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cellectar Biosciences, Inc. (CLRB) Financial Data
Cellectar Biosciences, Inc. has a market capitalization of $20.86M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -290.4%.
Valuation Metrics
Market Cap
$20.86M
Enterprise Value
$16.10M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+41.6%
Current Ratio
1.9x
Debt/Equity
32.4x
ROE
-290.4%
ROA
-103.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cellectar Biosciences, Inc. (CLRB) Business Model
About Cellectar Biosciences, Inc.
What They Do
Develops targeted cancer treatments using PDC technology.
Business Model
Cellectar Biosciences operates as a clinical-stage biopharmaceutical company, focusing on the discovery, development, and commercialization of innovative cancer therapies. The company generates revenue primarily through the advancement of its proprietary Phospholipid Drug Conjugate (PDC) delivery platform, which enhances the efficacy of therapeutic agents targeted specifically at cancer cells, thus reducing side effects and improving patient outcomes.
Additional Information
The company's leading candidate, iopofosine I 131, is currently in clinical trials for various cancers, including relapsed or refractory Waldenström's macroglobulinemia and multiple myeloma. Cellectar boasts a robust intellectual property portfolio that provides exclusivity for its PDC technology, positioning it well within the growing market for precision medicine in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
11
CEO
Mr. James V. Caruso
Country
United States
IPO Year
2005
Website
www.cellectar.comCellectar Biosciences, Inc. (CLRB) Latest News & Analysis
Latest News
Quick Summary
A recent study shows a favorable safety profile and preliminary clinical activity for a treatment in relapsed/refractory multiple myeloma, indicating potential investment interest in related biotech firms.
Why It Matters
Positive clinical results in relapsed/refractory multiple myeloma may indicate strong potential for drug approval, impacting stock prices and market confidence in the company involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A subset analysis shows an approximately 80% major response rate and response duration exceeding 16 months for patients treated with Iopofosine I-131 after BTKi therapy.
Why It Matters
High major response rates and prolonged duration of response for Iopofosine I 131 suggest strong potential for growth in oncology, impacting market dynamics and investment opportunities in biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cellectar Biosciences, Inc. (CLRB) held its Q1 2026 earnings call, providing updates on financial performance and business developments. Further details can be found in the full transcript.
Why It Matters
Cellectar Biosciences' Q1 2026 earnings call provides insights into financial performance, strategies, and pipeline developments, crucial for assessing growth potential and investment risks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2 months ago
Quick Summary
Positive 12-month follow-on data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia was announced, indicating potential efficacy in this patient population.
Why It Matters
Positive data for Iopofosine I 131 in r/r Waldenström Macroglobulinemia suggests potential market growth and revenue for the company, impacting stock value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
2 months ago
Quick Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will report Q1 2026 financial results and a corporate update on May 14, 2026, at 8:30 a.m. ET.
Why It Matters
Cellectar Biosciences' upcoming financial results and corporate update may impact stock performance, revealing insights into its drug development progress and financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cellectar Biosciences (NASDAQ:CLRB) shares rose following positive results from its Phase 2b CLOVER WaM clinical trial announced on Tuesday.
Why It Matters
Cellectar's share price increase reflects positive investor sentiment due to promising trial results, indicating potential for future growth and market opportunities.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About CLRB Stock
What is Cellectar Biosciences, Inc.'s (CLRB) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Cellectar Biosciences, Inc. (CLRB) has a median price target of $10.50. The highest price target is $15.00 and the lowest is $10.00.
Is CLRB stock a good investment in 2027?
According to current analyst ratings, CLRB has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLRB stock?
Wall Street analysts predict CLRB stock could reach $10.50 in the next 12 months. This represents a 318.3% increase from the current price of $2.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cellectar Biosciences, Inc.'s business model?
Cellectar Biosciences operates as a clinical-stage biopharmaceutical company, focusing on the discovery, development, and commercialization of innovative cancer therapies. The company generates revenue primarily through the advancement of its proprietary Phospholipid Drug Conjugate (PDC) delivery platform, which enhances the efficacy of therapeutic agents targeted specifically at cancer cells, thus reducing side effects and improving patient outcomes.
What is the highest forecasted price for CLRB Cellectar Biosciences, Inc.?
The highest price target for CLRB is $15.00 from at , which represents a 497.6% increase from the current price of $2.51.
What is the lowest forecasted price for CLRB Cellectar Biosciences, Inc.?
The lowest price target for CLRB is $10.00 from Kevin DeGeeter at Ladenburg Thalmann, which represents a 298.4% increase from the current price of $2.51.
What is the overall CLRB consensus from analysts for Cellectar Biosciences, Inc.?
The overall analyst consensus for CLRB is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are CLRB stock price projections?
Stock price projections, including those for Cellectar Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:16 AM UTC